

Resignation of Non-Executive Director

Sydney, Australia – 9 November 2022: Cannabis focused drug development and product innovation company Bod Australia Limited (“Bod” or “the Company”) (ASX: BOD) wishes to advise that Mr Hanno Cappon has resigned as Non-Executive Director with immediate effect.

Mr Cappon joined the Company’s Board in July 2021 as one of two Directors appointed by NewH2 and H&H pursuant to the investment agreement between the Company and NewH2 and H&H. Following the completion of the recent placement and entitlement offer, NewH2’s shareholding in the Company has reduced to less than ten per cent of the Company’s fully paid ordinary shares on issue and, in accordance with the investment agreement, the number of Directors appointed by NewH2 and H&H is to be reduced to a single Director. Mr Akash Bedi will remain on the Board as the appointee of NewH2 and H&H.

Bod has benefited from Mr Cappon’s extensive experience and advice and wishes him well for his future endeavours.

The Company continues to assess additional director candidates to ensure it has adequate diversity and the necessary skill sets to advance its current clinical trial pipeline and product commercialisation initiatives.

The Company advises that following Mr Cappon’s resignation, Resolution 15 from the agenda of the Annual General Meeting of Shareholders scheduled for 4.00pm (AEDT) on Monday 28 November 2022 has been withdrawn. Resolution 15 sought shareholder approval to issue Director options to Mr Cappon. The withdrawal of Resolution 15 will not affect the validity of the proxy form attached to the Notice of Annual General Meeting nor any proxy votes already submitted in respect of the remaining resolutions to be put to shareholders for approval.

This announcement has been approved by the Chief Executive Officer of Bod Australia Limited.

-ENDS-

About Bod Australia:

Bod Australia Limited (ASX:BOD) Bod is a cannabis focused drug development and product innovation company.

Bod is focused on progressing R&D and a defined clinical trial pathway to commercialise and deliver premium, scientifically proven and trusted products for the consumer and medical markets.

The Company has a number of existing partnerships with large corporate groups and collaborations with leading research partners to advance the use of CBD.

For more information please contact:

Jo Patterson
Chief Executive Officer
Info@bodaustralia.com
+61 2 9199 5018